Variable | Total SSc (n = 19) | lSSc (n = 10) | dSSc (n = 9) | HC (n = 6) | p Value (SSc v HC) |
---|---|---|---|---|---|
ANA, antinuclear antibody; CRP, C reactive protein; dSSc, diffuse systemic sclerosis; ESR, erythrocytic sedimentation rate; F, female; FEV1, forced expiratory volume; FVC, forced vital capacity; HC, healthy controls; lSSc, limited systemic sclerosis; M, male; RF, rheumatoid factor; SSc, systemic sclerosis. | |||||
*Values are mean (SD). | |||||
Age (years)* | 34. 8 (2.6) | 37.6 (15.7) | 33.6 (8.5) | 33.03 (7.2) | NS |
Sex (female: male ratio) | 18:1 | 9:1 | 9:0 | 5:1 | NS |
Duration (years)* | 04.8 (3.5) | 05.2 (3.9) | 4.5 (3.8) | – | – |
Arthralgia/Arthritis | 8/19 (42.1%) | 04/10 (40%) | 04/9 (44%) | Absent | <0.05 |
Raynaud’s phenomenon | 19/19 (100%) | 10/10 (100%) | 09/9 (100%) | Absent | <0.05 |
Pulmonary functions* | |||||
FVC | 60.9 (15.4) | 63.01 (16.3) | 58.0 (13.3) | 94.4 (7.7) | <0.05 |
FEV1 | 66.1 (16.1) | 54.4 (22.1) | 55.0 (13.9) | 95.2 (10.3) | <0.05 |
FEV1/FVC | 91.5 (10. 4) | 92.1 (6.6) | 86.5 (16.8) | 97.5 (6.9) | NS |
Proteinuria | 3/19 (15.8%) | 01/10 (10%) | 02/9 (22%) | Absent | <0.05 |
ESR* | |||||
First hour | 27.4 (16.3) | 30.5 (19.5) | 25.4 (15.2) | 08.5 (5.1) | <0.05 |
Second hour | 52.0 (22.1) | 54.7 (3) | 50.3 (20.2) | 13.3 (20.1) | <0.05 |
Positive RF | 05/19 (26.3%) | 03/10 (30%) | 02/9 (22%) | Absent | <0.05 |
Positive CRP | 05/19 (26.3%) | 02/10 (20%) | 03/9 (33%) | Absent | <0.05 |
Positive ANA | 19/19 (100%) | 10/10 (100%) | 09/9 (100%) | Absent | <0.05 |